FibroGen
Joanne Macatangay is a Clinical Finance Manager at FibroGen, Inc. since January 2021, showcasing a strong background in financial analysis and accounting. Prior experience includes roles as a Financial Analyst at Lyft, an Accountant at NGINX, Inc., and an Operations Analyst in Cleveland. Joanne has also worked as an English Second Language Teacher at both the Ministerio de Educacion, Cultura y Deporte and CAPS Home to Home. Earlier career highlights include serving as an Audit Senior and Audit Staff at Deloitte, along with an Event Planner Intern position at the Office of Career Management. Joanne holds a Bachelor of Science in Business Administration with a focus on Accounting from The Ohio State University and its Fisher College of Business.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.